Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Sep;89(3):686-697.
doi: 10.1007/s12020-025-04332-6. Epub 2025 Jun 23.

Height benefits after GnRHa treatment in girls aged over 6 years with central precocious puberty: a meta-analysis

Ming Chen  1 , Jie-Yu Sun  2 , Xing Ji  3 , Ming-Ming Ni  4
Affiliations
Meta-Analysis

Height benefits after GnRHa treatment in girls aged over 6 years with central precocious puberty: a meta-analysis

Ming Chen et al. Endocrine. 2025 Sep.

Abstract

Objective: The aim of this meta-analysis was to evaluate the impact of gonadotropin-releasing hormone analog (GnRHa) treatment on height outcomes in girls aged over 6 years with central precocious puberty (CPP).

Methods: A systematic search was performed across PubMed, Cochrane Library, Web of Science, MEDLINE, EMBASE, CNKI, and Wan Fang databases to identify eligible studies. The meta-analysis protocol was registered at PROSPERO, and the quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). A random-effects meta-analysis was used to synthesize data on height gain, final adult height (FAH), FAH standard deviation score (SDS), bone age, and the difference between FAH and target height (TH).

Results: Fifteen studies including 1270 girls were identified. The results indicated that GnRHa therapy significantly improves height outcomes in girls with CPP aged over 6 years. By effectively delaying pubertal progression and bone age maturation, GnRHa treatment enables these girls to achieve a greater FAH and potentially surpass their TH. Meta-analysis showed that the GnRHa treatment group demonstrated significantly greater height gain (WMD = 2.52, 95% CI [1.66, 3.37]), FAH (WMD = (WMD = 3.18, 95% CI [1.49, 4.87]), and FAH minus TH (WMD = 0.61, 95% CI [0.42, 0.79]) compared to the control group. Additionally, bone age (WMD = -1.02, 95%CI [-1.99, -0.06]) was significantly lower than the control group. However, FAH SDS showed no significant difference between the groups (WMD = 0.09, 95%CI [-0.40, 0.58]).

Conclusions: GnRHa treatment demonstrates substantial benefits in promoting height outcomes in girls over 6 years old with CPP. This meta-analysis contributes to the growing body of evidence supporting the efficacy of GnRHa in managing CPP and underscores the importance of early intervention to maximize height potential in affected individuals.

Keywords: Central precocious puberty; Final adult height; Girls aged over 6 years; Gonadotropin-releasing hormone analog; Height gain.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards. Conflict of interest: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. A.C. Latronico, V.N. Brito, J.C. Carel, Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol. 4(3), 265–274 (2016). - PubMed
    1. F. Guaraldi, G. Beccuti, D. Gori, L. Ghizzoni, Management of endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur. J. Endocrinol. 174(3), R79–R87 (2016). - PubMed
    1. V. De Sanctis, A.T. Soliman, S. Di Maio, N. Soliman, H. Elsedfy, Long-term effects and significant adverse drug reactions (Adrs) associated with the use of gonadotropin-releasing hormone analogs (Gnrha) for central precocious puberty: a brief review of literature. Acta Bio-Medica: Atenei Parmensis 90(3), 345–359 (2019). - PubMed
    1. A. Bereket, A critical appraisal of the effect of gonadotropin-releasing hormon analog treatment on adult height of girls with central precocious puberty. J. Clin. Res. Pediatr. Endocrinol. 9(Suppl 2), 33–48 (2017). - PubMed - PMC
    1. J. Fu, J. Zhang, R. Chen, X. Ma, C. Wang, L. Chen et al., Long-term outcomes of treatments for central precocious puberty or early and fast puberty in chinese girls. J. Clin. Endocrinol. Metab. 105(3), dgz027 (2020). - PubMed

Substances

LinkOut - more resources